GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

BioCardia BCDA · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.90

+6.19%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About BioCardia

From its filings with the US Securities and Exchange Commission

SEC filings

BioCardia is based in Sunnyvale, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker BCDA. The SEC classifies its business as biological products, (no diagnostic substances). In the fiscal year to 31 December 2025, it reported revenue of $0 and a net loss of $8.2m. At that date it held total assets of $3.4m and shareholders' equity of $895,000.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
13 Nov 1996
Employees
17
Head office
320 SOQUEL WAY, SUNNYVALE, CA, 94085
Incorporated in
DE
Classification
Biological Products, (No Diagnostic Substances)
Filer status
Non-accelerated filer<br>Smaller reporting company

Leadership

Pay as last reported

  • Mr. Andrew BlankIndependent Chairman of the Board$97,788
  • Dr. Peter AltmanPresident, Chief Executive Officer, Director, since 2002$746,237
  • Mr. David McclungChief Financial Officer$469,469
  • Mr. Edward GillisSenior Vice President - Devices$326,371
  • Mr. Jim AllenIndependent Director$49,288
  • Mr. Bill FacteauIndependent Director$24,688
  • Dr. Richard KrasnoIndependent Director$57,788
  • Mr. Jay MoyesIndependent Director$65,288
  • Dr. Simon StertzerIndependent Director$47,549

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • BioCardia's CardiAMP Cell Therapy System is in Phase III trials for ischemic systolic heart failure.
  • CardiALLO is an allogeneic off-the-shelf mesenchymal stem cell product candidate.
  • Helix Biotherapeutic Delivery System and Morph Deflectable Guide and Sheaths are key product offerings.

Weaknesses

  • BioCardia employs only 17 full-time employees as of the latest data.
  • The company has been listed since 13 November 1996 with limited recent growth.
  • CardiAMP is still in Phase III trials without approved commercialization.

Opportunities

  • The regenerative medicine sector shows significant growth potential in the Health Care industry.
  • CardiALLO's off-the-shelf nature could expand market reach in the biotechnology sector.
  • The Phase III trial success for CardiAMP may lead to new market opportunities.

Threats

  • Competition in the biotechnology sector remains intense with multiple players.
  • Regulatory hurdles could delay the approval of CardiAMP and CardiALLO.
  • The Health Care industry faces ongoing challenges with funding and reimbursement policies.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.